Arcturus Therapeutics
ARCT
137 hedge funds and large institutions have $477M invested in Arcturus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 28 closing their positions.
98% more call options, than puts
Call options by funds: $41.6M | Put options by funds: $21M
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
9% more capital inflows, than outflows
Capital inflows: $51.8M | Capital outflows: $47.6M
0.21% more ownership
Funds ownership: 95.01% → 95.22% (+0.21%)
5% less funds holding
Funds holding: 144 → 137 (-7)
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.27M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.61M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.26M |
| 4 |
ARK Investment Management
St. Petersburg,
Florida
|
+$2.53M |
| 5 |
Empire Life Investments
Toronto,
Ontario, Canada
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
-$11.5M |
| 2 |
Goldman Sachs
New York
|
-$7.64M |
| 3 |
Diversify Advisory Services
Sandy,
Utah
|
-$3.33M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.05M |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$2.64M |
ARCT Hedge Fund Activity: Q3 2025 in Review
137 of the 7,653 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2025, worth a combined $477M — up 42% from $336M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARCT and 22 opened new positions — a net loss of 6 holders — while 40 trimmed existing stakes and 49 added.
The largest buyer was Arrowstreet Capital, adding an estimated $8.27M. The largest seller was Woodline Partners, cutting an estimated $11.5M.
- 137 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2025, down from 144 in Q2 2025.
- Funds reported $477M of Arcturus Therapeutics stock for Q3 2025, up 42% quarter-over-quarter.
- 22 funds opened new Arcturus Therapeutics positions in Q3 2025 and 28 closed out, a net change of -6 holders.
- The largest Arcturus Therapeutics buyer in Q3 2025 was Arrowstreet Capital, an estimated $8.27M added.
- The largest Arcturus Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2025.